NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $53.74 +2.07 (+4.01 %) (As of 11/16/2018 04:00 PM ET)Previous Close$53.74Today's Range$51.16 - $54.3752-Week Range$39.07 - $57.92Volume972,630 shsAverage Volume1.16 million shsMarket Capitalization$6.89 billionP/E Ratio671.75Dividend YieldN/ABeta2.39 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases; Roche to develop therapeutics for the treatment of complement-mediated diseases; and drug research collaboration with SRI International for the intracellular delivery of nucleic acid-based drugs, as well as a research collaboration agreement with Cerveau Technologies, Inc. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California. Receive IONS News and Ratings via Email Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IONS Previous Symbol CUSIP46433010 Webwww.ionispharma.com Phone760-931-9200 Debt Debt-to-Equity Ratio0.74 Current Ratio7.99 Quick Ratio7.96 Price-To-Earnings Trailing P/E Ratio671.75 Forward P/E Ratio-282.84 P/E GrowthN/A Sales & Book Value Annual Sales$507.67 million Price / Sales14.56 Cash Flow$0.3898 per share Price / Cash137.85 Book Value$6.11 per share Price / Book8.80 Profitability EPS (Most Recent Fiscal Year)$0.08 Net Income$-5,960,000.00 Net Margins-7.52% Return on Equity-1.58% Return on Assets-0.55% Miscellaneous Employees547 Outstanding Shares137,570,000Market Cap$6.89 billion OptionableOptionable Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions What is Ionis Pharmaceuticals' stock symbol? Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS." How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals Inc (NASDAQ:IONS) issued its quarterly earnings results on Tuesday, November, 6th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.10. The company had revenue of $145.40 million for the quarter, compared to the consensus estimate of $146.77 million. Ionis Pharmaceuticals had a negative net margin of 7.52% and a negative return on equity of 1.58%. The firm's revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.02) EPS. View Ionis Pharmaceuticals' Earnings History. When is Ionis Pharmaceuticals' next earnings date? Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Ionis Pharmaceuticals. What price target have analysts set for IONS? 6 analysts have issued 1 year price targets for Ionis Pharmaceuticals' shares. Their forecasts range from $46.00 to $75.00. On average, they expect Ionis Pharmaceuticals' stock price to reach $54.3333 in the next twelve months. This suggests a possible upside of 1.1% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals. What is the consensus analysts' recommendation for Ionis Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals. Has Ionis Pharmaceuticals been receiving favorable news coverage? Media headlines about IONS stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ionis Pharmaceuticals earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. Who are some of Ionis Pharmaceuticals' key competitors? Some companies that are related to Ionis Pharmaceuticals include Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Bausch Health Companies (BHC), Genmab A/S (GNMSF), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT) and Beigene (BGNE). Who are Ionis Pharmaceuticals' key executives? Ionis Pharmaceuticals' management team includes the folowing people: Dr. Stanley T. Crooke, Founder, Exec. Chairman, CEO & Pres (Age 73)Dr. Brett P. Monia, Founder, COO & Sr. VP of Translational Medicine (Age 57)Ms. Elizabeth L. Hougen, CFO & Sr. VP of Fin. (Age 56)Dr. Richard S. Geary Ph.D., Sr. VP of Devel. (Age 60)Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 64) Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.91%), Baillie Gifford & Co. (6.51%), BlackRock Inc. (5.44%), First Trust Advisors LP (1.55%), American Century Companies Inc. (0.87%) and Wells Fargo & Company MN (0.85%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals. Which major investors are selling Ionis Pharmaceuticals stock? IONS stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Los Angeles Capital Management & Equity Research Inc., Franklin Resources Inc., Pinnacle Associates Ltd., Sector Gamma AS, SG Americas Securities LLC, AXA and Peregrine Capital Management LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals. Which major investors are buying Ionis Pharmaceuticals stock? IONS stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, First Trust Advisors LP, BlackRock Inc., DekaBank Deutsche Girozentrale, Point72 Asset Management L.P., EcoR1 Capital LLC, Canada Pension Plan Investment Board and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Ionis Pharmaceuticals. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ionis Pharmaceuticals' stock price today? One share of IONS stock can currently be purchased for approximately $53.74. How big of a company is Ionis Pharmaceuticals? Ionis Pharmaceuticals has a market capitalization of $6.89 billion and generates $507.67 million in revenue each year. The company earns $-5,960,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Ionis Pharmaceuticals employs 547 workers across the globe. What is Ionis Pharmaceuticals' official website? The official website for Ionis Pharmaceuticals is http://www.ionispharma.com. How can I contact Ionis Pharmaceuticals? Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200. MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 487 (Vote Outperform)Underperform Votes: 487 (Vote Underperform)Total Votes: 974MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/17/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?